Literature DB >> 15154005

Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site.

Bartosz Wasag1, Maria Debiec-Rychter, Patrick Pauwels, Michel Stul, Hilde Vranckx, Allan Van Oosterom, Anne Hagemeijer, Raf Sciot.   

Abstract

Gastrointestinal stromal tumors (GISTs) form a distinctive group of mesenchymal neoplasms, showing differentiation towards the interstitial cells of Cajal. Morphologically, GISTs vary from cellular spindle cell tumors to epithelioid or mixed, epithelioid and spindle cell variants. The genotypic features underlying the morphologic differences of GISTs with vs without epithelioid components are not well defined. Acquisition of activating mutations in KIT and PDGFRA has been reported as alternative oncogenic events in the pathogenesis of GISTs. In this study, a comprehensive KIT and PDGFRA mutational analysis was performed in a group of 28 epithelioid/mixed type tumors, in order to explore whether a specific KIT/PDGFRA mutational status segregates these neoplasms from spindle cell variant GISTs. All GISTs were primary neoplasms, 16 (57.1%) originated from the stomach and 12 (42.8%) from other locations. Histomorphologically, 14 GISTs showed an epithelioid and 14 a mixed cell type pattern. Mutational analysis included KIT exons 9, 11, 13, and 17, and PDGFRA exons 12 and 18 prescreening by denaturing high-performance liquid chromatography, followed by direct sequencing. Activating mutations of KIT were found in 14 (50%) GISTs, the majority being within exon 11 (n=11; 39.2%), and the other comprised exon 9 AY 502-503 duplications (n=2; 7.2%) and exon 17 Lys --> Aln822 missense mutations (n=1; 3.6%). Most of the KIT mutant tumors (n=11; 78.6%) originated from nongastric sites. Seven (25.0%) GISTs with no detectable KIT mutations demonstrated PDGFRA mutant isoforms, carrying either D842 V mutations (n=5) or exon 18 deletions (n=2). All GISTs harboring PDGFRA mutant isoforms originated from the stomach. In seven tumors, no detectable mutations were found; all but one of nonmutant tumors initiated from the stomach and exhibited an epithelioid morphology. These findings indicate that the mutational status of epithelioid/mixed GISTs associates with the anatomical site of the tumor.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15154005     DOI: 10.1038/modpathol.3800136

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  22 in total

1.  Relationship between gene mutations and protein expressions of PDGFR α and C-kit in gastrointestinal stromal tumors.

Authors:  Jun-Yi He; H X Tong; Y Zhang; J Y Wang; Y B Shao; J Zhu; Wei-Qi Lu
Journal:  Int J Clin Exp Med       Date:  2015-05-15

2.  CT and MRI findings in KIT-weak or KIT-negative atypical gastrointestinal stromal tumors.

Authors:  Ukihide Tateishi; Mototaka Miyake; Tetsuo Maeda; Yasuaki Arai; Kunihiko Seki; Tadashi Hasegawa
Journal:  Eur Radiol       Date:  2006-01-06       Impact factor: 5.315

3.  A quality control program for mutation detection in KIT and PDGFRA in gastrointestinal stromal tumours.

Authors:  Isabelle Hostein; Maria Debiec-Rychter; Sylvianne Olschwang; Pierre-Paul Bringuier; Louisa Toffolati; David Gonzalez; Sébastien Forget; Fabienne Escande; Lucyna Morzuch; Elena Tamborini; Nicolas Faur; Silvana Pilotti; Paolo Dei Tos; Jean-François Emile; Jean-Michel Coindre
Journal:  J Gastroenterol       Date:  2011-02-01       Impact factor: 7.527

4.  Improved detection of KIT exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.

Authors:  Jerzy Lasota; Bartosz Wasag; Sonja E Steigen; Janusz Limon; Markku Miettinen
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

5.  C-KIT mutations were closely associated with the response to Imatinib in Chinese advanced gastrointestinal stromal tumor patients.

Authors:  Jing Gao; Yunzhi Dang; Naiping Sun; Jian Li; Lin Shen
Journal:  Med Oncol       Date:  2012-07-20       Impact factor: 3.064

6.  In vivo imatinib sensitivity in a patient with GI stromal tumor bearing a PDGFRA deletion DIM842-844.

Authors:  Paul T Fanta; Jason K Sicklick; Bryan L Betz; Michael R Peterson
Journal:  J Clin Oncol       Date:  2014-03-17       Impact factor: 44.544

Review 7.  Gastrointestinal stromal tumours: origin and molecular oncology.

Authors:  Christopher L Corless; Christine M Barnett; Michael C Heinrich
Journal:  Nat Rev Cancer       Date:  2011-11-17       Impact factor: 60.716

8.  Molecular spectrum of c-KIT and PDGFRA gene mutations in gastro intestinal stromal tumor: determination of frequency, distribution pattern and identification of novel mutations in Indian patients.

Authors:  Firoz Ahmad; Purnima Lad; Simi Bhatia; Bibhu Ranjan Das
Journal:  Med Oncol       Date:  2014-12-07       Impact factor: 3.064

Review 9.  Genetic aberrations of gastrointestinal stromal tumors.

Authors:  Jilong Yang; Xiaoling Du; Alexander J F Lazar; Raphael Pollock; Kelly Hunt; Kexin Chen; Xishan Hao; Jonathan Trent; Wei Zhang
Journal:  Cancer       Date:  2008-10-01       Impact factor: 6.860

10.  Clinical outcomes of tumor bleeding in duodenal gastrointestinal stromal tumors: a 20-year single-center experience.

Authors:  Gyu Young Pih; Ji Yong Ahn; Ji Young Choi; Hee Kyong Na; Jeong Hoon Lee; Kee Wook Jung; Do Hoon Kim; Kee Don Choi; Ho June Song; Gin Hyug Lee; Hwoon-Yong Jung
Journal:  Surg Endosc       Date:  2020-03-13       Impact factor: 4.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.